Global mRNA Vaccines & Therapeutics Market Overview:
mRNA is a versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use led to transient expression of the encoded protein. This favorable safety profile makes mRNA exclusively attractive for vaccines and gene editing. mRNA is chemically well defined which ensures reproducible manufacturing at high yield, purity and activity. An improvement of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies. Some of the players profiled in the study are Argos Therapeutics (U.S), AstraZeneca (UK), Bayer (Germany), Boehringer Ingelheim (Germany), CRISPR Therapeutics (Switzerland), CureVac (Germany), ETheRNA immunotherapies (Belgium), Ethris (Germany), In-Cell-Art (France) and Intellia Therapeutics (U.S).
On the basis of geography, the market of mRNA Vaccines & Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2019. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Mechanism of Action, the sub-segment i.e. Bioengineered Vaccine will boost the mRNA Vaccines & Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Growth Drivers
- Rise in prevalence of chronic diseases like diabetes, tuberculosis, cancer and certain other cardiovascular conditions
- Government Support provided by various regions
- Rapid advancement in technologies particularly in the healthcare sector
- High failure rated accompanied with problems faced in drug delivery
- Business dynamics present in Asia Pacific is expected to provide lucrative opportunity
Key Market Developments:
Key players are implementing various strategies such as mergers & acquisitions, new product development, partnerships and others. Medical technology and healthcare companies are setting standards by providing mRNA vaccines & therapeutics with the help of various technological advancements
Manufacturers of mRNA vaccines & therapeutics, Suppliers of mRNA vaccines & therapeutics subcomponents, Wholesalers, distributers and retailers of mRNA vaccines & therapeutics, Pharmaceutical industry, Hospitals, Clinics, Research organizations and Governmental bodies
Major Objectives Focused through this Study
To define, describe, and forecast the Global mRNA Vaccines & Therapeutics market on the basis of product [Standardization of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine and Infection Prevention MRNA Vaccine] , application [Hospital, Clinic and Others], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the mRNA Vaccines & Therapeutics market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the mRNA Vaccines & Therapeutics industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Janssen (Belgium), Kernal Biologics (U.S), MaxCyte (U.S), Moderna Therapeutics (U.S), Novartis (Switzerland), Precision NanoSystems (Canada) and RaNa Therapeutics (U.S).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the mRNA Vaccines & Therapeutics market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.